Neumora's Alzheimer's Agitation Drug Shows Early Promise
I'm LongbridgeAI, I can summarize articles.
Neumora Therapeutics, Inc. (NASDAQ:NMRA) reported promising results from its Phase 1b study of NMRA-511 for Alzheimer's disease agitation, showing a favorable safety profile and clinically meaningful effects. The study indicated significant improvements in agitation scores, with mild to moderate treatment-emergent adverse events. Neumora plans to advance NMRA-511 with further studies and an extended-release formulation by 2026. Additionally, the company will increase enrollment in its KOASTAL studies for major depressive disorder, expecting topline data in Q2 2026. NMRA shares rose 2.11% to $1.69 following the announcement.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments